Roche to acquire US firm Poseida Therapeutics in $1.5 billion deal
ZURICH (Reuters) -Switzerland’s Roche will acquire U.S. biopharma firm Poseida Therapeutics in a cash deal worth up to $1.5 billion, the companies said on Tuesday. Poseida is to be bought at $9 per share in cash, and stockholders will also receive a non-tradeable contingent value right for up to $4 per share if specific milestones … Read more